Table 1.
Baseline characteristics of the European and Japanese trial populations (full analysis sets)
| |
European population [23] |
Japanese population [24] |
||
|---|---|---|---|---|
| DNG (n = 120) | GnRH analogue (n = 128) | DNG (n = 128) | GnRH analogue (n = 125) | |
| Age (years, mean ± SD) |
30.6 ± 6.2 |
31.0 ± 5.8 |
33.5 ± 6.9 |
33.8 ± 6.2 |
| Weight (kg, mean ± SD) |
62.5 ± 10.8 |
62.7 ± 9.6 |
52.1 ± 7.1 |
53.3 ± 8.2 |
| Lumbar BMD (g/cm2, mean ± SD) | 1.06 ± 0.1 (n = 26) | 1.07 ± 0.1 (n = 31) | 1.04 ± 0.1 (n = 41) | 1.03 ± 0.1 (n = 46) |
DNG, dienogest (2 mg/day); GnRH, gonadotropin-releasing hormone analogue; BMD, bone mineral density. GnRH analogues: European trial, leuprolide acetate 3.75 mg intramuscular injection, four-weekly; Japanese trial, buserelin acetate 3 × 300 μg/day, intranasally.